Product Details
Brilinta 90 mg Tikagrelor Tablets In Pakistan
Brilinta 90mg contains ticagrelor, an antiplatelet medicine that works by inhibiting the P2Y12 platelet receptor. It is prescribed to reduce the risk of cardiovascular events such as heart attack and stroke in certain patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It can also be used in specific patients with acute ischemic stroke or high-risk TIA.
Brilinta is a prescription medicine and carries an important bleeding warning. It should be used only under the supervision of a qualified healthcare professional.
Benefits
- Helps reduce the risk of heart attack and cardiovascular death in eligible patients with ACS or previous MI.
- Helps reduce the risk of stroke in certain approved patient groups.
- Can reduce the risk of stent thrombosis after stent placement for ACS.
- Provides antiplatelet activity by reducing platelet activation and aggregation.
- May be prescribed as part of an appropriate cardiovascular treatment plan.
Specifications
| Specification | Details |
|---|---|
| Product Name | Brilinta 90mg Tablets |
| Active Ingredient | Ticagrelor |
| Strength | 90mg |
| Drug Class | P2Y12 Platelet Inhibitor |
| Dosage Form | Oral Tablet |
| Main Uses | ACS, history of MI, selected stroke/TIA patients |
| Administration | Oral |
| Prescription Status | Prescription Medicine |
| Manufacturer/Marketer | AstraZeneca / verify local packaging |
| Available Strengths | 60mg and 90mg |
The current official prescribing information lists Brilinta in 60mg and 90mg tablet strengths.
How To Use
- Take Brilinta exactly as prescribed by your doctor.
- For ACS or a history of MI, the labeled regimen begins with a 180mg loading dose followed by 90mg twice daily during the first year; after one year, the labeled dose is 60mg twice daily. Other conditions have different regimens.
- Take doses at approximately the same times each day.
- If you miss a dose, take the next scheduled dose at its normal time rather than doubling the dose.
- Brilinta is commonly used with a maintenance aspirin dose of 75–100mg daily when prescribed for the relevant indications; do not change aspirin dosage without medical advice.
- Do not stop Brilinta suddenly without speaking to your doctor, particularly after a heart attack or stent procedure, because stopping treatment can increase cardiovascular risk.
Important Precautions
Brilinta can cause serious or potentially fatal bleeding. It should not be used in people with active pathological bleeding or a history of intracranial hemorrhage. Commonly reported adverse effects include bleeding and shortness of breath.
Why Choose Brilinta 90mg?
- Established Antiplatelet Medicine: Contains ticagrelor, a P2Y12 platelet inhibitor.
- Cardiovascular Protection: Used in specific patients to reduce cardiovascular risks.
- Post-ACS Use: The 90mg strength is specifically included in the labeled regimen during the first year following ACS.
- Evidence-Based Prescribing: Its indications, dosing, interactions, and safety warnings are documented in official prescribing information.
- Oral Tablet: Convenient tablet formulation for prescribed treatment.
